Johnson & Johnson Unveils Breakthrough Pulsed Field Ablation Data at APHRS 2025 to Transform Atrial Fibrillation Treatment

Johnson & Johnson MedTech has announced it will present new clinical and real-world data on its breakthrough pulsed field ablation (PFA) system the VARIPULSE™ Platform at the 2025 joint annual meeting of the Asia Pacific Heart Rhythm Society and the Japanese Heart Rhythm Society, taking place in Yokohama from November 12 to 15. The move highlights the company's growing commitment to improving outcomes in atrial fibrillation (AFib) care, a condition that affects millions worldwide.

The VARIPULSE™ Platform integrates three components: the VARIPULSE™ Catheter, TRUPULSE™ Generator, and the CARTO™ 3 Mapping System with dedicated software. Designed to deliver non-thermal ablation therapy with high precision, the platform offers a safer and more efficient option for treating Atrial fibrillation (AFib). It is already approved in over 20 countries, including the United States, Japan, China, Australia, and across Europe and Latin America. To date, more than 25,000 procedures have been performed using the system globally.

At APHRS 2025, Johnson & Johnson will unveil findings from multiple clinical trials and registries that explore the safety, efficacy, and workflow optimization of its healthcare PFA technology. Among the highlights is the QUEST AF study, which evaluates acute success rates in treating persistent AFib using very high-power, short-duration radiofrequency energy. The company will also present data from the VARIPURE (SECURE) study, which analyzes real-world procedural efficiency and detailed vein-level outcomes when using a novel variable-loop circular catheter.

Additional insights come from the admIRE registry, which examines how patient factors such as age, gender, and timing of diagnosis impact long-term success following catheter ablation. One session will also focus on same-day discharge protocols following PFA procedures, addressing growing demand for faster, safer outpatient care. The REAL AF registry further contributes evidence with sessions on first-pass vein isolation, adjunctive carina ablation, and the influence of anatomical variations on treatment effectiveness.

These studies reflect Johnson & Johnson's continued investment in building a complete body of evidence around its PFA platform. The company is also offering hands-on demos and expert-led sessions at the conference, aiming to accelerate clinical adoption across Asia and beyond.

By combining advanced technology with global data, Johnson & Johnson is positioning pulsed field ablation as a future standard in AFib treatment. With growing adoption and stronger evidence emerging, the company's push in this field may reshape how electrophysiologists treat heart rhythm disorders in the years to come.